Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

GBI Research
Published Date » 2013-07-31
No. Of Pages » 93
 GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis Therapeutics to 2019 Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth”. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of...
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Disease Overview 8
2.2 Epidemiology 8
2.3 Symptoms 9
2.4 Etiology 9
2.5 Pathophysiology 10
2.5.1 Blood Brain Barrier Degradation 10
2.5.2 Cellular Infiltration of the Central Nervous System 10
2.6 Co-morbidities/Complications 11
2.7 Diagnosis 12
2.7.1 McDonald Criteria 12
2.7.2 Physical Examination 13
2.7.3 MRI Scans 13
2.7.4 Lumbar Puncture 13
2.7.5 Other Diagnostic Tests 13
2.8 Prognosis 14
2.9 Treatment Efficacy 15
2.10 Treatment Options 15
2.10.1 Corticosteroids 16
2.10.2 Anti-neoplastic Drugs 16
2.10.3 Skeletal Muscle Relaxants 16
2.10.4 Pain Management in MS 17
2.11 Treatment Algorithm 17
2.12 Non-pharmacological Therapies 19

3 Therapeutic Landscape 20
3.1 Copaxone (glatiramer acetate) – Teva Pharmaceuticals 20
3.2 Betaseron (interferon beta 1b) – Bayer AG 21
3.3 Avonex (interferon beta 1a IM) – Biogen 22
3.4 Rebif (interferon beta 1a SC) – Merck Serono 23
3.5 Tysabri (natalizumab) – Biogen Idec/Elan Corporation 24
3.6 Gilenya (fingolimod hydrochloride) – Mitsubishi Tanabe and Novartis 25
3.7 Aubagio (Teriflunomide) – Genzyme Corporation and Sanofi-Aventis 26
3.8 Novantrone (mitoxantrone ) – Merck Serono 26
3.9 Conclusion 28
3.10 Unmet Need 28

4 Pipeline for Multiple Sclerosis Therapeutics 29
4.1 Overall Pipeline 29
4.2 Route of Administration 31
4.3 Molecular Targets within the MS Pipeline 32
4.4 Clinical Trials 34
4.4.1 Failure Rate of Developmental Programs 34
4.4.2 Clinical Trial Size 36
4.4.3 Clinical Trial Duration 38
4.5 Promising Pipeline Candidates 40
4.5.1 Lemtrada (alemtuzumab) – Genzyme and Bayer Schering Pharma 40
4.5.2 Tecfidera (dimethyl fumarate) – Biogen Idec 40
4.5.3 Laquinimod (laquinimod sodium) – Teva Pharmaceuticals 41
4.5.4 ocrelizumab – F. Hoffman-La Roche 42
4.5.5 daclizumab – Biogen Idec and Abbot Laboratories 42
4.5.6 firategrast – GlaxoSmithKline 43
4.5.7 Siponimod (BAF-312) – Novartis AG 44
4.6 Conclusion 44

5 Market Forecast to 2019 47
5.1 Geographical Markets 47
5.1.1 Key Developed Markets 47
5.1.2 US 50
5.1.3 Top Five EU Countries 52
5.1.4 Japan 56
5.2 Drivers and Barriers 58
5.2.1 Drivers 58
5.2.2 Barriers 59

6 Deals and Strategic Consolidations 61
6.1 Major Co-development Deals 61
6.1.1 Daiichi Sankyo Enters into an Agreement with Amplimmune 63
6.1.2 Karo Bio Enters into an Agreement with Pfizer 63
6.1.3 Proteostasis Enters into an Agreement with Elan 63
6.1.4 Lycera Enters into an Agreement with Merck 64
6.1.5 Facet Enters into an Agreement with Trubion 64
6.1.6 UCB Enters into an Agreement with Biogen 64
6.2 Major Licensing Deals 65
6.2.1 Addex Extends its Licensing Agreement with Merck 68
6.2.2 Biogen Enters into a Licensing Agreement with Acorda Therapeutics 69
6.2.3 Genzyme Enters into a Licensing Agreement with Bayer Healthcare 69
6.2.4 Novartis Enters into a Licensing Agreement with Peptimmune 69
6.2.5 Merck Serono Enters into a Licensing Agreement with Apitope Technology 69
6.2.6 Antisense Enters into a Licensing Agreement with Teva Pharmaceutical 70
6.2.7 BioMS Medical Corp Enters into a Licensing Agreement with Eli Lilly 70
6.2.8 Biotica Enters into an Agreement with Wyeth 70

7 Appendix 71
7.1 Pipeline Product Tables by Phase 71
7.2 Market Forecasting Data Tables to 2019 81
7.3 Market Definition 85
7.4 Abbreviations 85
7.5 References 86
7.6 Methodology 89
7.7 Secondary Research 90
7.8 Therapeutic Landscape 90
7.9 Epidemiology-Based Forecasting 91
7.10 Market Size by Geography 92
7.11 Pipeline Analysis 93
7.12 Contact Us 93
7.13 Disclaimer 93

List of Tables

Table 1: McDonald Criteria, Multiple Sclerosis, 2013 12
Table 2: Expanded Disability Status Scale, Multiple Sclerosis, 2013 14
Table 3: Multiple Sclerosis, Global, Market Forecast, ($bn), 2012–2019 81
Table 4: Multiple Sclerosis, US, Market Forecast, ($bn), 2012–2019 81
Table 5: Multiple Sclerosis, UK, Market Forecast, ($bn), 2012–2019 82
Table 6: Multiple Sclerosis, France, Market Forecast, ($bn), 2012–2019 82
Table 7: Multiple Sclerosis, Germany, Market Forecast, ($bn), 2012–2019 83
Table 8: Multiple Sclerosis, Italy, Market Forecast, ($bn), 2012–2019 83
Table 9: Multiple Sclerosis, Spain, Market Forecast, ($bn), 2012–2019 84
Table 10: Multiple Sclerosis, Japan, Market Forecast, ($bn), 2012–2019 84

List of Figures

Figure 1: Treatment Algorithm, Global, Multiple Sclerosis, 2013 18
Figure 2: Multiple Sclerosis, Marketed Products Heat Map 27
Figure 3: Overall Pipeline for Multiple Sclerosis 30
Figure 4: Routes of Administration in the Pipeline 31
Figure 5: Molecular Targets of Pipeline Molecules 32
Figure 6: Molecular Targets in MS Pipeline by Phase of Development 33
Figure 7: Failure Rate of MS Clinical Trials, 2006–2013 35
Figure 8: Reasons for Clinical Trial Failure, 2006–2013 36
Figure 9: Clinical Trial Size by Product and Phase, 2006–2013 37
Figure 10: Clinical Trial Duration by Phase and Molecule Type, 2006–2013 39
Figure 11: Multiple Sclerosis, Pipeline Product Heat Map 45
Figure 12: Multiple Sclerosis, Marketed Product Heat Map, 2012–2019 46
Figure 13: Multiple Sclerosis Market, Global, Patient Volumes (‘000) and Market Size ($bn), 2012–2019 49
Figure 14: Multiple Sclerosis Market, US, Patient Volumes (‘000), Annual Cost of Treatment ($) and Market Size ($bn), 2012–2019 51
Figure 15: Multiple Sclerosis Market, EU5, Patient Population (‘000), 2012–2019 53
Figure 16: Multiple Sclerosis Market, EU5, Annual Cost of Treatment ($), 2012–2019 54
Figure 17: Multiple Sclerosis Market, EU5, Market Size ($bn), 2013–2019 55
Figure 18: Multiple Sclerosis Market, Japan, Patient Volume (‘000), Annual Cost of Treatment ($) and Market Size ($bn), 2013–2019 57
Figure 19: Multiple Sclerosis, Co-development Deals by Geography, Value and Year, 2006–2013 61
Figure 20: Multiple Sclerosis, Co-Development Deal Frequency by Phase and Molecule Type 2006–2013 62
Figure 21: Multiple Sclerosis, Licensing Deals by Geography, Value and Year, 2006–2013 66
Figure 22: Multiple Sclerosis, Licensing Deal frequency by Phase and Molecule Type, 2006–2013 67
Figure 23: Multiple Sclerosis, Licensing Deal Value by Molecule Type and Mechanism of Action, 2006–2013 68
Figure 24: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Discovery) 71
Figure 25: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-I 72
Figure 26: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-II 73
Figure 27: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-III 74
Figure 28: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -I 75
Figure 29: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -II 76
Figure 30: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - I 77
Figure 31: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - II 78
Figure 32: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase III) 79
Figure 33: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Registration) 79
Figure 34: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Undisclosed) 80
Figure 35: Multiple Sclerosis Market, Global, GBI Research Market Sizing Model 92

Upcoming Reports:

Poland: market of lathes for removing metal
By - Williams and Marshal Strategy
tics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market participants, the price fluctuations, the growth and demand drivers of the market and the factors, influencing its development. Last but not least, the report presents a general overview of the economy of Poland in 2008-2012 and a forecast for its development in the medium term. The report on the lathes for removing metal market in Poland includes: Analysis and dynamics of the economy of Poland; Forecast...
Prenatal Diagnostics Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Prenatal diagnostics is a procedure for testing of diseases before the birth of a child, to determine certain inheritable disorders such as chromosome abnormalities, Down’s syndrome, genetic diseases, neural tube defects, and other conditions. It can be conducted by various procedures of screening, common testing, genetic testing and other measures in cases of high risk related to the birth of a child. The global market for prenatal diagnostics in 2010 was USD 5.35 billion and it is expected to grow with a CAGR of 4.35% and generate revenues of USD 5.89 billion by...
Automotive Cockpit Electronics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Electronics in automotive industry has increased ease of driving, safety and also vies to provide quality infotainment. Automotive electronics industry provides solutions for perfect combination of design, feel, ergonomics and quality through electronics. The solutions provided include instrument clusters, displays, infotainment & navigation, and telematics. Cockpit electronics has a large market and has seen a high growth rate in recent times. This trend in growth for automotive cockpit electronics market is expected to continue over the coming years. Regionally, North America...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...